The metabolism of Paricalcitol can be decreased when combined with Atomoxetine. The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. Polythiazide may increase the hypercalcemic activities of Paricalcitol. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. The metabolism of Paricalcitol can be decreased when combined with Clemastine. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Lovastatin. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. Metolazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The metabolism of Paricalcitol can be increased when combined with Carbamazepine. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. The metabolism of Paricalcitol can be decreased when combined with Bortezomib. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. The metabolism of Paricalcitol can be decreased when combined with Olaparib. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). The metabolism of Paricalcitol can be increased when combined with Nevirapine. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. The metabolism of Paricalcitol can be increased when combined with Rifampicin. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. Danazol may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. The metabolism of Paricalcitol can be decreased when combined with Ranolazine. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. The metabolism of Paricalcitol can be increased when combined with Rifabutin. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. Paricalcitol may increase the arrhythmogenic activities of Deslanoside. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. Paricalcitol may increase the arrhythmogenic activities of Ouabain. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. Indapamide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Primidone. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. The metabolism of Paricalcitol can be decreased when combined with Sildenafil. Quinethazone may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Phenytoin. The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Isradipine. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane.